The activity of thyme essential oil against Acinetobacter spp

Central European Journal of Biology

Volumn 6, Issue 3, 2011, Pages 405-413

  Łysakowska, Monika ^a   Denys, Andrzej ^a   Sienkiewicz, Monika ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antibacterial activity; Minimal inhibitory concentration; Multiresistant strains; Thyme oil

Indexed keywords

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); THYMUS VULGARIS;

EID: 79955465783     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-011-0008-x     Document Type: Article

References (30)

1. Chastre J., Evolving problems with resistant pathogens, Clin. Microbiol. Infect., 2008, 14, 3-14.
2. Kalemba D., Kunicka A., Antibacterial and antifungal properties of essential oils, Curr. Med. Chem., 2003, 10, 813-829.
3. Giordani R., Regli P., Kaloustian J., Portugal H., Potentation of antifungal activity of amphoteracin B by essential oil from Cinnamonium cassia, Phytother. Res., 2006, 20, 58-61.
4. Lis-Balchin M., Deans S., Hart S., Bioactive Geranium oils from different commercial sources, J. Essent. Oil Res., 2007, 8, 281-290.
5. Rosato A., Vitali C., De Laurentis N., Armenise D., Antonietta Milillo M., Antibacterial effect of some essential oils administered alone or in combination with Norfloxacin, Phytomedicine, 2007, 14, 727-732.
6. Shin S., Kim J., In vitro inhibitory activities of essential oils from two Korean Thymus species against antibiotic-resistant pathogens, Arch. Pharm. Res., 2005, 28, 897-901.
7. King L., Swiatlo E., Swiatlo A., Swiatlo A., McDaniel L. S., Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii, FEMS Immunol. Med. Microbiol., 2009, 55, 414-421.
8. Gaynes R., Edwards J., Overview of nosocomial infections caused by gram-negative bacilli, Clin. Infect. Dis., 2005, 41, 848-854.
9. Falagas M., Karveli E., The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications, Clin. Microbiol. Infect., 2007, 13, 117-119.
10. Bernabeu-Wittel M., Pichardo C., Garcia-Curiel A., Pachón-Ibáñez M., Ibáñez-MartÍnez J., Jimenez-Mejias M., et al., Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia, Clin. Microbiol. Infect., 2005, 11, 319-325.
11. Ecker J., Massire C., Hall T., Ranken R., Penella T., Agasino Ivy C., et al., Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry, J. Clin. Microbiol., 2006, 44, 2921-2932.
12. Wisplinghoff H., Edmond M., Pfaller M., Jones R., Wenzel R., Seifert H., Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility, Clin. Infect. Dis., 2000, 31, 690-697.
13. Higgins P., Wisplinghoff H., Krut O., Seifert A., PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU, Clin. Microbiol. Infect., 2007, 13, 1199-1201.
14. th Ed., Allured Publishing Corporation, Carol Stream, IL, USA, 2007.
15. Joulain D., König W. A., The atlas of spectral data of sesquiterpene hydrocarbons, E. B.-Verlag, Hamburg, 1998.
16. Clinical and Laboratory Standard Institute (CLSI), Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. CLSI document M100-S16, Clinical and Laboratory Standard Institute, Wayne, Pennsylvania, USA, 2006.
17. th Ed., Polish Pharmaceutical Society, Warsaw, 2008.
18. th Ed., Council of Europe, Strasbourg, 2008.
19. Ye J.-J., Huang C.-T., Shie S.-S., Huang P.-Y., Su L.-H., Chiu C. H., Multidrug resistant Acinetobacter baumannii: Risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains, PLoS ONE, 2010, 5, e9947.
20. nd Ed., Pharmaceutical Press, London, 2006.
21. rd Ed., Churchill Livingstone, London 1999.
22. Routsi C., Pratikaki M., Platsouka E., Sotiropoulou C., Nanas S., Markaki V., et al., Carbapenemresistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes, Infection, 2010, 38, 173-180.
23. Chastre J., Wolff M., Fagon J., Chevret S., Thomas F., Wermert D., et al., Comparison of 8 vs 15 days of antibiotic therapy for ventilatorassociated pneumonia in adults: a randomized trial, J. Am. Med. Assoc., 2003, 290, 2588-2598.
24. Meyer E., Schwab F., Schroeren-Boersch B., Gastmeier P., Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008, Crit. Care, 2010, 14, R113-R121.
25. Dent L., Marshall D., Pratap S., Hulette R., Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital, BMC Infect. Dis., 2010, 10, e196.
26. Falagas M., Koletsi P., Bliziotis I., The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa, J. Med. Microbiol., 2006, 55, 1615-1617.
27. Fabio A., Cermelli C., Fabio G., Nicoletti P., Quaglio P., Screening of the antibacterial effects of a variety of essential oils on microorganisms responsible for respiratory infections, Phytother. Res., 2007, 21, 374-377.
28. Bekhechi C., Bekkara F. A., Abdelouahid D. E., Tomi F., Casanova J., Composition and Antibacterial Activity of the Essential Oil of Thymus fotanesii Boiss. et Reut. from Algeria, J. Essent. Oil Res., 2007, 19, 594-596.
29. Rosooli I., Mirmostafa S., Bacterial susceptibility to and chemical composition of essential oils from Thymus kotschyanus and Thymus persicus, J. Agr. Food Chem., 2003, 51, 2200-2205.
30. Coelho da Costa A., Cavalcanti dos Santos B., Filho L., de Oliveira Lima E., Antibacterial activity of the essential oil of Origanum vulgare L. (Lamiaceae) against bacterial multiresistant strains isolated from nosocomial patients, Rev. Brasil. Farmacogn., 2009, 19, 236-241.